Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17611547
[patent_doc_number] => 20220153826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING VIRUS-ASSOCIATED INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 17/525338
[patent_app_country] => US
[patent_app_date] => 2021-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525338
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/525338 | Methods and compositions for treating virus-associated inflammation | Nov 11, 2021 | Issued |
Array
(
[id] => 17843776
[patent_doc_number] => 11433118
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Long-acting VEGF inhibitors for intraocular neovascularization
[patent_app_type] => utility
[patent_app_number] => 17/522318
[patent_app_country] => US
[patent_app_date] => 2021-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 24
[patent_no_of_words] => 16041
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522318
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/522318 | Long-acting VEGF inhibitors for intraocular neovascularization | Nov 8, 2021 | Issued |
Array
(
[id] => 17563197
[patent_doc_number] => 20220127346
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => Methods of Safe Administration of Anti-Tau Antibody
[patent_app_type] => utility
[patent_app_number] => 17/509910
[patent_app_country] => US
[patent_app_date] => 2021-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12862
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17509910
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/509910 | Methods of Safe Administration of Anti-Tau Antibody | Oct 24, 2021 | Pending |
Array
(
[id] => 17666416
[patent_doc_number] => 11360101
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => In vitro method for diagnosing central nervous system injury
[patent_app_type] => utility
[patent_app_number] => 17/503441
[patent_app_country] => US
[patent_app_date] => 2021-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 24
[patent_no_of_words] => 12067
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17503441
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/503441 | In vitro method for diagnosing central nervous system injury | Oct 17, 2021 | Issued |
Array
(
[id] => 17733332
[patent_doc_number] => 20220218791
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => NON-LEAKING OR MINIMALLY-LEAKING CHOROIDAL OR RETINAL REVASCULARIZATION
[patent_app_type] => utility
[patent_app_number] => 17/484656
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20726
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484656
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/484656 | NON-LEAKING OR MINIMALLY-LEAKING CHOROIDAL OR RETINAL REVASCULARIZATION | Sep 23, 2021 | Abandoned |
Array
(
[id] => 17458793
[patent_doc_number] => 20220072097
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => PEPTIDES AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/482750
[patent_app_country] => US
[patent_app_date] => 2021-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19345
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17482750
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/482750 | PEPTIDES AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | Sep 22, 2021 | Pending |
Array
(
[id] => 17355308
[patent_doc_number] => 20220016104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/480789
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17480789
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/480789 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | Sep 20, 2021 | Pending |
Array
(
[id] => 17828436
[patent_doc_number] => 20220265740
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT
[patent_app_type] => utility
[patent_app_number] => 17/479968
[patent_app_country] => US
[patent_app_date] => 2021-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20880
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479968
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/479968 | TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT | Sep 19, 2021 | Pending |
Array
(
[id] => 17443766
[patent_doc_number] => 20220064271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => METHODS FOR TREATING TAUOPATHIES
[patent_app_type] => utility
[patent_app_number] => 17/464190
[patent_app_country] => US
[patent_app_date] => 2021-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22318
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464190
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/464190 | METHODS FOR TREATING TAUOPATHIES | Aug 31, 2021 | Abandoned |
Array
(
[id] => 17272947
[patent_doc_number] => 20210379145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => COMPOSITIONS FOR INCREASING RESILIENCE TO TRAUMATIC BRAIN INJURY
[patent_app_type] => utility
[patent_app_number] => 17/403025
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17898
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403025
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/403025 | COMPOSITIONS FOR INCREASING RESILIENCE TO TRAUMATIC BRAIN INJURY | Aug 15, 2021 | Pending |
Array
(
[id] => 17687728
[patent_doc_number] => 20220195020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => METHODS OF TREATING ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/394053
[patent_app_country] => US
[patent_app_date] => 2021-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28849
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394053
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/394053 | METHODS OF TREATING ALZHEIMER'S DISEASE | Aug 3, 2021 | Abandoned |
Array
(
[id] => 17297915
[patent_doc_number] => 20210393754
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS
[patent_app_type] => utility
[patent_app_number] => 17/390584
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 81094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17390584
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/390584 | Personalized immunotherapy against several neuronal and brain tumors | Jul 29, 2021 | Issued |
Array
(
[id] => 18947060
[patent_doc_number] => 11890333
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => Personalized immunotherapy against several neuronal and brain tumors
[patent_app_type] => utility
[patent_app_number] => 17/390583
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 81145
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17390583
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/390583 | Personalized immunotherapy against several neuronal and brain tumors | Jul 29, 2021 | Issued |
Array
(
[id] => 17343673
[patent_doc_number] => 20220010004
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/443779
[patent_app_country] => US
[patent_app_date] => 2021-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70878
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17443779
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/443779 | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE | Jul 26, 2021 | Pending |
Array
(
[id] => 17228646
[patent_doc_number] => 20210355202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => ANTIBODY BINDING ACTIVE ALPHA-SYNUCLEIN
[patent_app_type] => utility
[patent_app_number] => 17/381661
[patent_app_country] => US
[patent_app_date] => 2021-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17381661
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/381661 | Antibody binding active a-synuclein | Jul 20, 2021 | Issued |
Array
(
[id] => 17358063
[patent_doc_number] => 20220018859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => TEST METHODS FOR DIAGNOSING CHRONIC WASTING DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/377989
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4655
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/377989 | TEST METHODS FOR DIAGNOSING CHRONIC WASTING DISEASE | Jul 15, 2021 | Abandoned |
Array
(
[id] => 17443779
[patent_doc_number] => 20220064284
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-GPRC5D ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/376874
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14472
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376874
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/376874 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-GPRC5D ANTIBODIES | Jul 14, 2021 | Pending |
Array
(
[id] => 18656200
[patent_doc_number] => 20230302080
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => METHOD FOR PRODUCING A MAMMALIAN BRAIN PROTEIN HYDROLYSATE
[patent_app_type] => utility
[patent_app_number] => 18/004287
[patent_app_country] => US
[patent_app_date] => 2021-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8583
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004287
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/004287 | METHOD FOR PRODUCING A MAMMALIAN BRAIN PROTEIN HYDROLYSATE | Jul 12, 2021 | Pending |
Array
(
[id] => 18405817
[patent_doc_number] => 20230167168
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-06-01
[patent_title] => HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413
[patent_app_type] => utility
[patent_app_number] => 17/355529
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17355529
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/355529 | High affinity antibodies targeting tau phosphorylated at serine 413 | Jun 22, 2021 | Issued |
Array
(
[id] => 18405817
[patent_doc_number] => 20230167168
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-06-01
[patent_title] => HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413
[patent_app_type] => utility
[patent_app_number] => 17/355529
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17355529
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/355529 | High affinity antibodies targeting tau phosphorylated at serine 413 | Jun 22, 2021 | Issued |